Next Article in Journal
Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo
Next Article in Special Issue
Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
Previous Article in Journal
Post-Embryonic Phase Transitions Mediated by Polycomb Repressive Complexes in Plants
Previous Article in Special Issue
Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 14
10.3390/ijms22147536
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies

Int. J. Mol. Sci. 2021, 22(14), 7536; https://doi.org/10.3390/ijms22147536
by Inez Wens 1,*,†, Ibo Janssens 1,†, Judith Derdelinckx 1,2, Megha Meena 1, Barbara Willekens 1,2,‡ and Nathalie Cools 1,3,‡
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2021, 22(14), 7536; https://doi.org/10.3390/ijms22147536
Submission received: 31 May 2021 / Revised: 25 June 2021 / Accepted: 28 June 2021 / Published: 14 July 2021
(This article belongs to the Special Issue Tolerogenic Cell-Based Therapy: Where We Stand?)

Round 1

Reviewer 1 Report

The manuscript by Inez et al. summarizes current knowledge on the treatment options for multiple sclerosis with immune system cell-based therapies. In general, the paper is very well prepared and reads well. However, I have only two comments.



  1. Lines 64-65 The authors should list what are the side effects of DMTs therapy. And just in the context of these side effects highlight the potential benefits of using immune system cells.

 

  1. Some cells (e.g. MSCs) require propagation ex-vivo before transfer to the patient. I am curious if any compounds are being used in therapies or ongoing trials that would improve the properties of these cells?

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Excellent review very well written. Would benefit from proof-reading as a few grammatical errors were evident and the inclusion of  figures or table to break up the long text. Some specific points/suggestions for improvement:

  1. Cell therapy section for the treatment of MS would benefit from a table of all the clinical studies to date with the different cell types.
  2. Section 2.1 is very comprehensive could you add some detail of the practicalities e.g how much bone marrow or blood can be obtained? is this sufficient for a single or multiple treatments
  3. In the HSCT section (line 150-154) a discrepancy is highlighted in the literature regarding B cells- can the authors speculate why there is a disagreement?
  4. In section 2.5.3 what about practicalities wrt NKT cell based therapies can enough of these be isolated and expanded? 
  5. would be great to have an illustration of how antigens can be delivered via cell carriers.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop